Authors: | Clarke, J. L.; Pao, W.; Wu, N.; Miller, V.; Lassman, A. B. |
Article Title: | High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer |
Abstract: | Leptomeningeal metastases (LM) occur in 5-10% of patients with solid tumors and are associated with a dismal prognosis. We describe LM from lung adenocarcinoma harboring a mutation in the epidermal growth factor receptor (EGFR) gene that confers sensitivity to the EGFR tyrosine kinase inhibitors (EGFR-TKIs) erlotinib and gefitinib. The CSF concentration of EGFR-TKIs achieved by standard daily dosing may be insufficient for therapeutic effect. However, intermittent (pulsatile) high dose administration (1000-1500 mg/week) achieves a higher CSF concentration than standard dosing, and successfully controlled LM in this patient. © 2010 Springer Science+Business Media, LLC. |
Keywords: | adult; treatment outcome; middle aged; gene mutation; mutation; case report; erlotinib; drug dose comparison; paclitaxel; temozolomide; drug megadose; adenocarcinoma; carboplatin; lung non small cell cancer; lung neoplasms; epidermal growth factor receptor; lung cancer; receptor, epidermal growth factor; cetuximab; protein kinase inhibitors; lung adenocarcinoma; meningeal neoplasms; gefitinib; brain metastasis; egfr; quinazolines; drug sensitivity; pemetrexed; leptomeningeal metastases; drug cerebrospinal fluid level; leptomeningeal metastasis |
Journal Title: | Journal of Neuro-Oncology |
Volume: | 99 |
Issue: | 2 |
ISSN: | 0167-594X |
Publisher: | Springer |
Date Published: | 2010-09-01 |
Start Page: | 283 |
End Page: | 286 |
Language: | English |
DOI: | 10.1007/s11060-010-0128-6 |
PUBMED: | 20146086 |
PROVIDER: | scopus |
PMCID: | PMC3973736 |
DOI/URL: | |
Notes: | --- - "Cited By (since 1996): 4" - "Export Date: 20 April 2011" - "CODEN: JNODD" - "Source: Scopus" |